快而精医药(QGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

QGEN 快而精医药

盘前交易 02-04 04:06:25 EST

51.89

-0.29

-0.56%

最高52.30	最低51.25	成交量284.05万
今开51.91	昨收52.18	日振幅2.01%
总市值106.89亿	流通市值105.87亿	总股本2.06亿
成交额1.47亿	换手率1.39%	流通股本2.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"QGEN","market":"US","secType":"STK","nameCN":"快而精医药","latestPrice":51.89,"timestamp":1770152400000,"preClose":52.18,"halted":0,"volume":2840532,"delay":0,"changeRate":-0.005557684936757362,"floatShares":204028534,"shares":205998950,"eps":1.935644,"marketStatus":"盘前交易","change":-0.29,"latestTime":"02-04 04:06:25 EST","open":51.91,"high":52.3,"low":51.25,"amount":147115035.287244,"amplitude":0.020123,"askPrice":51.8,"askSize":200,"bidPrice":51.76,"bidSize":200,"shortable":3,"etf":0,"ttmEps":1.935644,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770215400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":51.89,"dividendRate":0.005043,"postHourTrading":{"tag":"盘后","latestPrice":51.89,"preClose":51.89,"latestTime":"17:31 EST","volume":453008,"amount":23506593.7,"timestamp":1770157890526,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1507359035086007,"impliedVol":0.5143,"impliedVolPercentile":0.9799},"requestUrl":"/m/hq/s/QGEN","defaultTab":"news","newsList":[{"id":"1161840846","title":"财报前瞻｜快而精医药本季度营收预计增1.83%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1161840846","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161840846?lang=zh_cn&edition=full","pubTime":"2026-01-28 10:45","pubTimestamp":1769568337,"startTime":"0","endTime":"0","summary":"快而精医药将于2026年02月04日发布最新季度财报，市场关注收入与盈利韧性及新产品周期表现。市场一致预期显示，本季度快而精医药总收入预计为5.30亿美元，同比增1.83%；EBIT预计为1.56亿美元，同比降2.57%；调整后每股收益预计为0.63美元，同比降3.97%，财务模型显示盈利端承压而收入保持温和增长，净利率与毛利率的季度预测未披露。机构普遍认为本季度收入同比增长约1.83%，但EBIT与EPS同比小幅下滑，核心关注费用投入与产品组合变化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜快而精医药本季度营收预计增1.83%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QGEN"],"gpt_icon":0},{"id":"1165538075","title":"快而精医药上调2025财年调整后每股收益目标至约2.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165538075","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165538075?lang=zh_cn&edition=full","pubTime":"2025-11-05 02:30","pubTimestamp":1762281043,"startTime":"0","endTime":"0","summary":"11月4日电 - 快而精医药公告：*快而精医药第三季度调整后每股收益为0.61美元*快而精医药 - 2025年第三季度净销售额为5.33亿美元，每股收益为0.60美元*快而精医药全年调整后每股收益展望为2.38美元*快而精医药 - 重申2025年全年净销售增长约为4-5%的展望*快而精医药：将2025财年调整后摊薄每股收益目标上调至约2.38美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909593.SGD","LU2125909247.SGD","LU2433249047.HKD","QGEN","LU1923622614.USD","BK4121"],"gpt_icon":0},{"id":"2581488687","title":"快而精医药盘中异动 股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581488687","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581488687?lang=zh_cn&edition=full","pubTime":"2025-11-05 02:26","pubTimestamp":1762280760,"startTime":"0","endTime":"0","summary":"北京时间2025年11月05日02时26分，快而精医药股票出现异动，股价大幅跳水5.30%。截至发稿，该股报43.26美元/股，成交量138.752万股，换手率0.64%，振幅7.98%。机构评级方面，在所有23家参与评级的机构中，39%的券商给予买入建议，61%的券商给予持有建议，无券商给予卖出建议。快而精医药股票所在的生命科学行业中，整体涨幅为0.39%。快而精近90%的收入来自耗材，其余收入来自仪器仪表和相关服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110502260094ef158a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110502260094ef158a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","QGEN","LU2125909593.SGD","LU2125909247.SGD","LU2433249047.HKD","LU1923622614.USD"],"gpt_icon":0},{"id":"1186975664","title":"快而精医药获得美国监管批准，推出高通量Qiastat-Dx Rise系统","url":"https://stock-news.laohu8.com/highlight/detail?id=1186975664","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186975664?lang=zh_cn&edition=full","pubTime":"2025-09-02 13:45","pubTimestamp":1756791936,"startTime":"0","endTime":"0","summary":"快而精医药(Qiagen NV)宣布，其高通量Qiastat-Dx Rise系统已获得美国监管部门批准，这将扩大患者获得快速综合征检测的机会。\n这一新获批的系统代表着该公司在诊断技术领域的重要进展，能够为医疗机构提供更高效的检测解决方案，进一步提升患者的诊疗体验和医疗服务质量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909593.SGD","QGEN","LU2433249047.HKD","LU2125909247.SGD","LU1923622614.USD","BK4121"],"gpt_icon":0},{"id":"2558468121","title":"快而精医药2025财年第二财季实现净利润96.25百万美元，同比增加152.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558468121","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558468121?lang=zh_cn&edition=full","pubTime":"2025-08-11 00:01","pubTimestamp":1754841700,"startTime":"0","endTime":"0","summary":"8月11日，快而精医药公布财报，公告显示公司2025财年第二财季净利润为96.25百万美元，同比增加152.60%；其中营业收入为5.34亿美元，同比增加7.66%，每股基本收益为0.44美元。从资产负债表来看，快而精医药总负债23.18亿美元，其中短期债务5.59亿美元，资产负债比为2.52，流动比率为1.62。机构评级：截至2025年8月11日，当前有19家机构对快而精医药目标价做出预测，其中目标均价为52.13美元，其中最低目标价为43.95美元，最高目标价为61.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000409a6de0849&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000409a6de0849&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QGEN"],"gpt_icon":0},{"id":"2512174796","title":"Baird：下调Qiagen(QGEN.US)评级，由优于大市调整至中性评级, 目标价由52.00美元调整至42.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512174796","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512174796?lang=zh_cn&edition=full","pubTime":"2025-02-19 18:13","pubTimestamp":1739960009,"startTime":"0","endTime":"0","summary":"Baird：下调Qiagen(QGEN.US)评级，由优于大市调整至中性评级, 目标价由52.00美元调整至42.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19181348262789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["QGEN"],"gpt_icon":0},{"id":"2510051839","title":"快而精医药2024财年实现净利润83.59百万美元，同比减少75.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510051839","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510051839?lang=zh_cn&edition=full","pubTime":"2025-02-09 00:00","pubTimestamp":1739030450,"startTime":"0","endTime":"0","summary":"2月9日，快而精医药公布财报，公告显示公司2024财年净利润为83.59百万美元，同比减少75.49%；其中营业收入为19.78亿美元，同比增加0.66%，每股基本收益为--。从资产负债表来看，快而精医药总负债21.22亿美元，其中短期债务53.48百万美元，资产负债比为2.69，流动比率为3.61。机构评级：截至2025年2月9日，当前有18家机构对快而精医药目标价做出预测，其中目标均价为50.36美元，其中最低目标价为45.00美元，最高目标价为55.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250209000058a23e5b6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250209000058a23e5b6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QGEN"],"gpt_icon":0},{"id":"2501222235","title":"大摩：下调Qiagen评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2501222235","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501222235?lang=zh_cn&edition=full","pubTime":"2025-01-06 20:17","pubTimestamp":1736165833,"startTime":"0","endTime":"0","summary":"大摩：下调Qiagen(QGEN.US)评级，由增持调整至持股观望评级,目标价由50.00美元调整至48.00美元。快而精医药(QGEN.US)公司简介：QIAGEN NV是一家控股公司，致力于提供从样品到洞察的解决方案，使客户能够从包含生命构建块的样品中获得有价值的分子见解。该公司的样品技术从血液、组织和其他材料中分离和处理DNA、RNA和蛋白质。牢固的分析技术使这些生物分子可见并准备好进行分析。它的生物信息学软件和知识库解释数据，以报告相关的、可操作的见解。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106202540aba06b52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106202540aba06b52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QGEN"],"gpt_icon":0},{"id":"2490042168","title":"快而精医药盘中异动 快速上涨5.08%报46.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490042168","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490042168?lang=zh_cn&edition=full","pubTime":"2024-12-11 02:41","pubTimestamp":1733856064,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日02时41分，快而精医药股票出现波动，股价快速拉升5.08%。截至发稿，该股报46.57美元/股，成交量73.3585万股，换手率0.33%，振幅2.41%。快而精医药股票所在的生命科学行业中，整体涨幅为0.27%。其相关个股中，Inotiv, Inc.、快而精医药、Neogenomics, Inc.涨幅较大，Applied Dna Sciences, Inc.、Inotiv, Inc.、Mainz Biomed N.V.较为活跃，换手率分别为8.30%、6.95%、2.66%，振幅较大的相关个股有Inotiv, Inc.、Applied Dna Sciences, Inc.、Mainz Biomed N.V.，振幅分别为23.03%、16.30%、15.61%。Qiagen 近 90% 的收入来自消耗品，其余收入来自仪器和相关服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211024104984b1841&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211024104984b1841&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2125909247.SGD","BK4121","LU1923622614.USD","QGEN","LU2125909593.SGD","LU2433249047.HKD"],"gpt_icon":0},{"id":"2483309434","title":"快而精医药2024财年第三财季实现净利润98.06百万美元，同比增加26.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483309434","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483309434?lang=zh_cn&edition=full","pubTime":"2024-11-16 00:00","pubTimestamp":1731686425,"startTime":"0","endTime":"0","summary":"11月16日，快而精医药公布财报，公告显示公司2024财年第三财季净利润为98.06百万美元，同比增加26.01%；其中营业收入为5.02亿美元，同比增加5.46%，每股基本收益为0.44美元。从资产负债表来看，快而精医药总负债27.40亿美元，其中短期债务5.55亿美元，资产负债比为2.29，流动比率为2.18。机构评级：截至2024年11月16日，当前有18家机构对快而精医药目标价做出预测，其中目标均价为51.47美元，其中最低目标价为45.00美元，最高目标价为60.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000130abc51401&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000130abc51401&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QGEN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qiagen.com","stockEarnings":[{"period":"1week","weight":-0.043},{"period":"1month","weight":0.0909},{"period":"3month","weight":0.1191},{"period":"6month","weight":0.0193},{"period":"1year","weight":0.1244},{"period":"ytd","weight":0.0962}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Qiagen N.V.是一家荷兰的控股公司，其子公司是样品检验与化验技术（Sample and Assay Technologies）的主要提供者。该公司是Sample to Insight解决方案的全球领导者，为两个广泛的客户群中的500,000多个客户提供服务：分子诊断（人类保健）和生命科学（学术界，制药研发和工业应用，主要是法医学）。公司在超过100个国家经营其产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.466667,"avgChangeRate":0.026288},{"month":2,"riseRate":0.6,"avgChangeRate":0.028213},{"month":3,"riseRate":0.37931,"avgChangeRate":0.010359},{"month":4,"riseRate":0.586207,"avgChangeRate":0.018871},{"month":5,"riseRate":0.517241,"avgChangeRate":0.019556},{"month":6,"riseRate":0.517241,"avgChangeRate":0.004976},{"month":7,"riseRate":0.633333,"avgChangeRate":0.038168},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.005901},{"month":9,"riseRate":0.366667,"avgChangeRate":-0.01054},{"month":10,"riseRate":0.433333,"avgChangeRate":0.017787},{"month":11,"riseRate":0.6,"avgChangeRate":0.034255},{"month":12,"riseRate":0.566667,"avgChangeRate":-0.000367}],"exchange":"NYSE","name":"快而精医药","nameEN":"Qiagen NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"快而精医药(QGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供快而精医药(QGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"快而精医药,QGEN,快而精医药股票,快而精医药股票老虎,快而精医药股票老虎国际,快而精医药行情,快而精医药股票行情,快而精医药股价,快而精医药股市,快而精医药股票价格,快而精医药股票交易,快而精医药股票购买,快而精医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"快而精医药(QGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供快而精医药(QGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}